• Just-approved Orladeyo Now Being Shipped to US Patients
  • Takhzyro Approved in China for Routine Prevention of HAE Attacks
  • Oral PHA121 May Be Better On-demand HAE Treatment Than Firazyr, Early Data Show
  • FDA Approves Orladeyo, 1st Oral Treatment to Prevent HAE Attacks
  • New Generic Version of Firazyr Now Available in US to Treat Acute HAE Attacks
  • NORD Push for Rare Disease Advisory Councils Focus of Dec. 16 Public Meeting
  • Injectable Preventive Treatments Weigh on Patients and Caregivers, Surveys Show
  • Takhzyro Safely Prevents HAE Attacks Over Long Term, Extension Study Shows
  • Survey Finds COVID-19 Disrupted Care, Well-Being of Rare Disease Patients in Europe
  • Latest NORD Webinar Offers Insights on Starting Nonprofit, Patient Registry
  • Takhzyro, for HAE Attacks, Moves Closer to Public Funding Across Canada
  • Berotralstat Available to Eligible Patients in UK Through Early Access Program